Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy
Oncology Pharma Inc. (OTC: ONPH) is actively assembling a shortlist of contract research organizations (CROs) to aid in developing a research plan for a combination therapeutic platform for treating cancer, following a licensing agreement with SYBLEU Inc. announced on February 26, 2021. This collaboration aims to identify multiple treatment indications. The selected CRO will strategize with Oncology Pharma on intellectual property and target the first indication for therapeutic use. The company commits to advancing cancer therapeutics while facing operational and financial uncertainties.
- Engaging CROs for research plan development.
- Worldwide license agreement with SYBLEU Inc. for cancer treatment.
- Current negative operating cash flows.
- Need for additional funding which may be highly dilutive.
- Uncertain market acceptance for new technologies.
San Francisco, CA, March 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH): Today, the company announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization.
On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer.
A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.
ABOUT ONCOLOGY PHARMA, INC
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Email: info@oncology-pharma.com
Website: www.oncology-pharma.com
FAQ
What is the latest announcement from Oncology Pharma (ONPH) regarding research organizations?
What is the significance of the SYBLEU Inc. agreement for Oncology Pharma (ONPH)?
What are the financial risks mentioned in the press release for Oncology Pharma (ONPH)?
How does Oncology Pharma (ONPH) plan to further its cancer treatment plans?
